Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase EARLY_PHASE1 3Phase NA 2Phase 1/2 2Phase 1 2

Status

Completed 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1

Conditions

Ototoxicity 1Hemangioma, Cavernous, Central Nervous System 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Carboplatin 112Cisplatin 111pembrolizumab 110Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × Atorvastatin × Clear all
NCT06553157 2026-01-20

Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy

Minia University

Phase 1/2 Completed
56 enrolled

Ototoxicity

NCT02603328 2025-08-22

AT CASH EPOC

University of Chicago

Phase 1/2 Completed
80 enrolled 19 charts
CNS

Hemangioma, Cavernous, Central Nervous System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡